作者
Vivian SK Nishihira, Barbara D Fontana, Francine R Ianiski, Hemilaine S de Almeida, Christopher P Posser, Juliane B Dias, Crystian B Parodi, Manoela M Piva, Anderson Gris, Ricardo E Mendes, Marta MMF Duarte, Michele R Sagrillo, Cristiane Luchese, Virginia C Rech, Rodrigo A Vaucher
发表日期
2018/11/1
期刊
Biomedicine & Pharmacotherapy
卷号
107
页码范围
1259-1267
出版商
Elsevier Masson
简介
Meloxicam is an anti-inflammatory drug that has a potential protective effect in many common diseases. However, this molecule is quickly eliminated from the body due to it short half-life. One way to overcome this problem is to incorporate meloxicam into lipid-core nanocapsules which may increase it anti-inflammatory effects. In view of this, the objective of this work was to evaluate the potential toxicity and safety of these novel nanomaterials both in vitro and in vivo. Here, we evaluated the effects of uncoated meloxicam-loaded nanocapsules (M-NC), uncoated and not loaded with meloxicam or blank (B-NC), PEGylated meloxicam-loaded lipid-core nanocapsules (M-NCPEG), blank PEGylated lipid-core nanocapsules (B-NCPEG) and free meloxicam (M-F) in vitro through the analysis of cell viability, caspase activity assays and gene expression of perforin and granzyme B. Meanwhile, the in vivo safety was assessed …
引用总数
201920202021202220231212